XstalBio Ltd is an advanced drug delivery company specialising in the formulation and stabilisation of therapeutic proteins, peptides, DNA and vaccines.

XstalBio has developed proprietary formulation technology that has the potential to create new product opportunities, improve the therapeutic value, accelerate the development and extend the product life-cycles of protein-based drugs.

Protein coated micro crystals (PCMC) provide a highly differentiated method for preparing biomolecules as stable solid-state formulations and the particles may be engineered for a wide range of delivery options including parenteral, pulmonary, sustained release and transdermal routes.

XstalBio Ltd is already collaborating with leading pharmaceutical and biotechnology companies and we continue to seek pharmaceutical partners for licensing and co-development of the PCMC technology for their proprietary molecules.

XstalBio can also provide vaccine, pharmaceutical and biotechnology companies active in the delivery and stabilisation of proteins or vaccines an immediate competitive advantage by offering significant advancement in Circular Dichroism (CD) analysis. Conventional CD is used to elucidate the structural aspects of protein conformation in solution but cannot be applied to particles.

An innovative, yet simple, rotating CD cell holder has been developed by XstalBio to provide rapid, reliable information on the secondary and tertiary structure of proteins in the solid state. This powerful tool enables faster and more cost effective analysis of formulations; yet can be easily slotted into existing CD instruments and used with freely available software packages.

Evaluation and utilisation of the CD technology is a straight-forward technology transfer process with full training being offered to key users.